Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2014

01-01-2014

Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells

Authors: Shifra Ash, Shai Yarkoni, Nadir Askenasy

Published in: Immunologic Research | Issue 1/2014

Login to get access

Abstract

One of the therapeutic approaches to type 1 diabetes (T1D) focuses on enhancement of regulatory T cell (Treg) activity, either by adoptive transfer or supplementation of supporting cytokines such as interleukin-2 (IL-2). In principle, this therapeutic design would greatly benefit of concomitant reduction in pathogenic cell burden. Experimental evidence indicates that physiological recovery from lymphopenia is dominated by evolution of effector and cytotoxic cells, which abolishes the therapeutic efficacy of Treg cells. Targeted and selective depletion of effector T cells has been achieved with killer Treg using Fas ligand protein and a fusion protein composed of IL-2 and caspase-3, which showed remarkable efficacy in modulating the course of inflammatory insulitis in NOD mice. We emphasize a critical consideration in design of therapeutic approaches to T1D, immunomodulation without lymphoreduction to avoid the detrimental consequences of rebound recovery from lymphopenia.
Literature
1.
2.
3.
Askenasy EM, Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity? Autoimmun Rev. 2013;12(5):633–7.CrossRefPubMed
4.
Kaminitz A, Stein J, Yaniv I, Askenasy N. The vicious cycle of apoptotic beta-cell death in type 1 diabetes. Immunol Cell Biol. 2007;85(8):582–9.CrossRefPubMed
5.
6.
Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013;14(5):322–32.CrossRefPubMed
7.
von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol. 2013;172(2):186–202.PubMedCentralCrossRef
8.
Askenasy N. Hematopoietic transplants for disease suppression and cure in type 1 diabetes. Cur Stem Cell Res Ther. 2013;8(4):333–9.CrossRef
9.
Askenasy EM, Askenasy N, Askenasy JJ. Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun Rev. 2010;9(10):687–90.CrossRefPubMed
10.
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun. 2009;33(3–4):255–9.CrossRefPubMed
11.
Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun. 2009;33(2):83–91.CrossRefPubMed
12.
Kaminitz A, Mizrahi M, Yaniv I, Stein J, Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun. 2010;35(2):145–52.CrossRefPubMed
13.
Yolcu ES, Kaminitz A, Ash S, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T regulatory cell homeostasis and suppression. Immunol Cell Biol. 2008;86(8):650–8.CrossRefPubMed
14.
Bayer AL, Jones M, Chirinos J, de Armas L, Schreiber TH, Malek TR, Levy RB. Host CD4+ CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood. 2009;113(3):733–43.PubMedCentralCrossRefPubMed
15.
Adeegbe D, Bayer AL, Levy RB, Malek TR. Cutting edge: allogeneic CD4+ CD25+ Foxp3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol. 2006;176(12):7149–53.CrossRefPubMed
16.
Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. BioEssays. 2008;30(9):875–88.CrossRefPubMed
17.
18.
19.
Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, Malek TR, Levy RB. Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol. 2011;41(12):3467–78.PubMedCentralCrossRefPubMed
20.
Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665–74.CrossRefPubMed
21.
Daniel C, von Boehmer H. Extrathymic generation of regulatory T cells—chances and challenges for prevention of autoimmune disease. Adv Immunol. 2011;112:177–213.CrossRefPubMed
22.
Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+ CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun. 2005;24(1):55–62.CrossRefPubMed
23.
von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing–remitting disease? Nat Rev Immunol. 2007;7(12):988–94.CrossRef
24.
Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev. 2008;7(5):370–5.CrossRefPubMed
25.
Askenasy N. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity. Autoimmun Rev. 2013;12(10):972–5.CrossRefPubMed
26.
Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun. 2011;37(1):39–47.CrossRefPubMed
27.
Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N. Killer regulatory T cells ameliorate inflammatory insulitis in diabetic NOD mice through local and systemic immunomodulation. Int Immunol. 2013;25(8):485–94.CrossRefPubMed
28.
Yarkoni S, Sagiv Y, Kaminitz A, Farkas DL, Askenasy N. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis. Eur J Immunol. 2009;39(10):2850–64.CrossRefPubMed
29.
Yarkoni S, Kaminitz A, Sagiv Y, Yaniv I, Askenasy N. Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. Diabetologia. 2010;53(2):356–68.CrossRefPubMed
30.
Yarkoni S, Prigozhina TB, Slavin S, Askenasy N. IL-2 targeted therapy ameliorates the severity of graft versus host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol Blood Marrow Transplant. 2012;18(4):523–35.CrossRefPubMed
Metadata
Title
Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells
Authors
Shifra Ash
Shai Yarkoni
Nadir Askenasy
Publication date
01-01-2014
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2014
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8476-x

Other articles of this Issue 1/2014

Immunologic Research 1/2014 Go to the issue

OriginalPaper

Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A

OriginalPaper

Discrimination of T-cell subsets and T-cell receptor repertoire distribution

Erratum

Erratum to: The role of activation-induced deaminase in antibody diversification and genomic instability

OriginalPaper

Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer

Erratum

Erratum to: Semaphorin7A: branching beyond axonal guidance and into immunity

OriginalPaper

IgA attenuates anaphylaxis and subsequent immune responses in mice: possible application of IgA to vaccines